cinacalcet 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
calcium-sensing receptors (CaSR) agonists	647	226256-56-0

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: cinacalcet mimpara cinacalcet hydrochloride sensipar AMG 073 AMG-073 KRN1493 cinacalcet HCl	Cinacalcet is a calcimimetic agent that increases the sensitivity of the calcium-sensing receptor to activation by extracellular calcium. It directly lowers PTH levels by increasing the sensitivity of the calcium sensing receptor to extracellular calcium. The reduction in PTH is associated with a concomitant decrease in serum calcium levels. Molecular weight: 357.42 Formula: C22H22F3N CLOGP: 6.35 LIPINSKI: 1 HAC: 1 HDO: 1 TPSA: 12.03 ALOGS: -6.81 ROTB: 7 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

cinacalcet
mimpara
cinacalcet hydrochloride
sensipar
AMG 073
AMG-073
KRN1493
cinacalcet HCl

Cinacalcet is a calcimimetic agent that increases the sensitivity of the calcium-sensing receptor to activation by extracellular calcium. It directly lowers PTH levels by increasing the sensitivity of the calcium sensing receptor to extracellular calcium. The reduction in PTH is associated with a concomitant decrease in serum calcium levels.

Molecular weight: 357.42
Formula: C22H22F3N
CLOGP: 6.35
LIPINSKI: 1
HAC: 1
HDO: 1
TPSA: 12.03
ALOGS: -6.81
ROTB: 7

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
60	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	0.10 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	0.10 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	7.19 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	20 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	17.60 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	18.30 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.05 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	19.90 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Oct. 22, 2004	EMA
March 8, 2004	FDA	AMGEN

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hospitalisation	8449.97	21.13	2562	25060	82519	63378881
Product dose omission issue	6762.93	21.13	2814	24808	231499	63229901
Laboratory test abnormal	6192.07	21.13	1573	26049	25339	63436061
Adverse drug reaction	1182.65	21.13	611	27011	79103	63382297
Blood parathyroid hormone increased	886.97	21.13	216	27406	2822	63458578
Intentional product misuse	862.72	21.13	453	27169	60464	63400936
Blood parathyroid hormone abnormal	487.79	21.13	85	27537	147	63461253
Arteriovenous fistula site complication	332.69	21.13	70	27552	443	63460957
Hospice care	323.84	21.13	124	27498	7808	63453592
Hypocalcaemia	273.69	21.13	171	27451	31542	63429858
Death	266.66	21.13	535	27087	373846	63087554
Calciphylaxis	257.02	21.13	82	27540	2990	63458410
Living in residential institution	256.31	21.13	57	27565	483	63460917
Blood calcium increased	230.87	21.13	102	27520	9248	63452152
Adverse event	211.51	21.13	199	27423	67360	63394040
Rehabilitation therapy	206.33	21.13	60	27562	1590	63459810
Nausea	204.14	21.13	820	26802	853651	62607749
Decreased appetite	196.84	21.13	374	27248	250678	63210722
Parathyroid tumour benign	196.75	21.13	49	27573	704	63460696
Hypophagia	193.34	21.13	137	27485	31122	63430278
Malaise	174.79	21.13	484	27138	415470	63045930
Transplant	164.60	21.13	43	27579	755	63460645
Renal transplant	154.22	21.13	46	27576	1334	63460066
Blood calcium decreased	150.00	21.13	110	27512	26341	63435059
Blood calcium abnormal	149.26	21.13	44	27578	1224	63460176
Vomiting	145.06	21.13	552	27070	559065	62902335
Parathyroidectomy	131.65	21.13	29	27593	234	63461166
Blood parathyroid hormone decreased	130.29	21.13	70	27552	9721	63451679
Hungry bone syndrome	130.19	21.13	25	27597	91	63461309
Nephrogenic systemic fibrosis	126.49	21.13	54	27568	4502	63456898
Unevaluable investigation	118.51	21.13	21	27601	42	63461358
Fatigue	110.56	21.13	135	27487	887893	62573507
Peritonitis bacterial	106.98	21.13	49	27573	4830	63456570
Hypercalcaemia	105.39	21.13	92	27530	28230	63433170
Arthralgia	100.58	21.13	62	27560	569648	62891752
Rheumatoid arthritis	90.16	21.13	5	27617	253814	63207586
Brown tumour	87.83	21.13	16	27606	40	63461360
Blood phosphorus increased	86.39	21.13	37	27585	3108	63458292
Dialysis	84.33	21.13	54	27568	10373	63451027
Gastrointestinal tube insertion	81.73	21.13	27	27595	1100	63460300
Contraindicated product administered	81.49	21.13	3	27619	217645	63243755
Joint swelling	77.86	21.13	23	27599	327643	63133757
Mastication disorder	75.59	21.13	30	27592	2076	63459324
Hepatic enzyme increased	75.02	21.13	3	27619	202325	63259075
Parathyroid tumour malignant	74.40	21.13	13	27609	23	63461377
Pyrexia	73.94	21.13	58	27564	470420	62990980
Arthropathy	71.45	21.13	9	27613	234783	63226617
Hyperparathyroidism	71.12	21.13	31	27591	2718	63458682
Pain	70.42	21.13	135	27487	740493	62720907
Abdominal discomfort	70.33	21.13	301	27321	320584	63140816
Skin induration	69.51	21.13	32	27590	3191	63458209
Sinusitis	68.21	21.13	9	27613	226644	63234756
Systemic lupus erythematosus	66.08	21.13	7	27615	208911	63252489
Product use issue	65.78	21.13	9	27613	220511	63240889
Blood phosphorus abnormal	64.33	21.13	15	27607	160	63461240
Condition aggravated	57.77	21.13	54	27568	402163	63059237
Arteriovenous fistula occlusion	57.37	21.13	16	27606	363	63461037
Glossodynia	56.54	21.13	6	27616	178870	63282530
Treatment failure	55.12	21.13	10	27612	199033	63262367
Therapeutic product effect decreased	55.04	21.13	9	27613	193178	63268222
Hypervolaemia	52.01	21.13	63	27559	28350	63433050
Unevaluable event	50.95	21.13	85	27537	51301	63410099
Skin hypertrophy	50.09	21.13	26	27596	3365	63458035
Gastrostomy	48.29	21.13	16	27606	658	63460742
Skin fibrosis	47.87	21.13	17	27605	863	63460537
Blue toe syndrome	47.36	21.13	14	27608	393	63461007
Swelling	47.04	21.13	31	27591	275347	63186053
Peritonitis	46.98	21.13	47	27575	17107	63444293
Stomatitis	45.56	21.13	4	27618	138721	63322679
Enteral nutrition	45.07	21.13	9	27613	42	63461358
Parathyroid disorder	44.61	21.13	15	27607	646	63460754
Hyperphosphataemia	44.39	21.13	21	27601	2227	63459173
Skin tightness	44.22	21.13	26	27596	4290	63457110
Toxicity to various agents	43.37	21.13	27	27595	247223	63214177
Neonatal hypocalcaemia	42.85	21.13	8	27614	24	63461376
Rash	42.05	21.13	116	27506	560755	62900645
Neutropenia	42.04	21.13	12	27610	174993	63286407
Surgery	41.91	21.13	64	27558	35848	63425552
Abdominal pain upper	41.61	21.13	189	27433	206255	63255145
Weight increased	41.08	21.13	32	27590	260760	63200640
End stage renal disease	40.58	21.13	29	27593	6664	63454736
Febrile neutropenia	40.05	21.13	3	27619	118446	63342954
Product use in unapproved indication	39.96	21.13	14	27608	179066	63282334
Drug ineffective	39.93	21.13	279	27343	1044486	62416914
Wrong technique in product usage process	38.14	21.13	84	27538	62256	63399144
Wound	37.76	21.13	12	27610	163251	63298149
Injection site pain	37.07	21.13	6	27616	129794	63331606
Pelvic deformity	35.85	21.13	10	27612	227	63461173
Cerebrovascular accident	34.99	21.13	115	27507	107909	63353491
Contusion	34.74	21.13	11	27611	150033	63311367
Alopecia	34.19	21.13	59	27563	337477	63123923
Drug hypersensitivity	33.62	21.13	52	27570	310635	63150765
Thyroid operation	33.20	21.13	9	27613	183	63461217
Arteriovenous fistula site infection	32.90	21.13	7	27615	47	63461353
Neonatal cholestasis	32.78	21.13	7	27615	48	63461352
White blood cell count decreased	32.56	21.13	10	27612	139094	63322306
Peritoneal dialysis complication	32.35	21.13	14	27608	1206	63460194
Arteriovenous fistula thrombosis	31.71	21.13	9	27613	218	63461182
Hyperparathyroidism tertiary	31	21.13	6	27616	23	63461377
Wheezing	30.73	21.13	3	27619	95592	63365808
Joint contracture	30.69	21.13	15	27607	1709	63459691
Parathyroid hyperplasia	30.64	21.13	8	27614	140	63461260
Dysphagia	29.30	21.13	95	27527	88490	63372910
Alanine aminotransferase increased	29.17	21.13	5	27617	103765	63357635
Neuropathy peripheral	28.80	21.13	7	27615	113660	63347740
Musculoskeletal stiffness	28.62	21.13	23	27599	184595	63276805
Chronic kidney disease-mineral and bone disorder	28.40	21.13	7	27615	96	63461304
Arteriovenous fistula site haemorrhage	27.83	21.13	8	27614	203	63461197
Nephrocalcinosis	27.38	21.13	12	27610	1066	63460334
Treatment noncompliance	27.15	21.13	54	27568	37271	63424129
Lower respiratory tract infection	26.79	21.13	12	27610	132295	63329105
Cardiac operation	26.47	21.13	17	27605	3281	63458119
Dyspnoea	25.94	21.13	175	27447	661138	62800262
Discomfort	25.76	21.13	21	27601	167353	63294047
Shunt occlusion	25.72	21.13	10	27612	655	63460745
Thrombosis in device	25.46	21.13	16	27606	2974	63458426
Malignant neoplasm progression	25.32	21.13	3	27619	82118	63379282
Migraine	24.97	21.13	7	27615	103339	63358061
Headache	24.62	21.13	168	27454	633073	62828327
Blister	24.42	21.13	13	27609	129801	63331599
Adjusted calcium decreased	24.16	21.13	7	27615	183	63461217
Shunt stenosis	24.05	21.13	9	27613	531	63460869
Peripheral swelling	23.83	21.13	50	27572	265892	63195508
Hypersensitivity	23.81	21.13	58	27564	292627	63168773
COVID-19	23.30	21.13	10	27612	113093	63348307
Platelet count decreased	22.78	21.13	11	27611	116111	63345289
Fibrosis	22.78	21.13	17	27605	4175	63457225
High turnover osteopathy	22.73	21.13	5	27617	40	63461360
Osteoarthritis	22.05	21.13	7	27615	95336	63366064
Aspartate aminotransferase increased	22.02	21.13	6	27616	90271	63371129
Skin hyperpigmentation	21.55	21.13	19	27603	5902	63455498
Impaired healing	21.23	21.13	9	27613	102533	63358867

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Product dose omission issue	7274.77	21.73	2732	19631	116979	34817589
Hospitalisation	6662.80	21.73	2127	20236	54775	34879793
Laboratory test abnormal	5869.17	21.73	1539	20824	18852	34915716
Adverse drug reaction	1025.01	21.73	457	21906	28885	34905683
Intentional product misuse	676.85	21.73	399	21964	45212	34889356
Blood parathyroid hormone increased	658.68	21.73	160	22203	1354	34933214
Blood parathyroid hormone abnormal	485.57	21.73	85	22278	77	34934491
Arteriovenous fistula site complication	378.87	21.73	82	22281	385	34934183
Hypocalcaemia	217.49	21.73	155	22208	24134	34910434
Adverse event	210.60	21.73	138	22225	18739	34915829
Transplant	210.41	21.73	57	22306	769	34933799
Blood calcium increased	209.95	21.73	81	22282	3513	34931055
Parathyroidectomy	186.11	21.73	35	22328	64	34934504
Hospice care	176.45	21.73	87	22276	6853	34927715
Blood parathyroid hormone decreased	153.31	21.73	51	22312	1429	34933139
Abdominal discomfort	153.20	21.73	190	22173	59645	34874923
Living in residential institution	152.17	21.73	39	22324	418	34934150
Blood calcium abnormal	148.45	21.73	40	22323	528	34934040
Nausea	141.55	21.73	507	21856	339401	34595167
Calciphylaxis	139.03	21.73	44	22319	1048	34933520
Blood calcium decreased	133.06	21.73	82	22281	10002	34924566
Hypophagia	132.05	21.73	115	22248	23907	34910661
Rehabilitation therapy	122.57	21.73	38	22325	844	34933724
Vomiting	112.90	21.73	381	21982	247240	34687328
Renal transplant	112.73	21.73	43	22320	1806	34932762
Parathyroid tumour benign	109.61	21.73	24	22339	120	34934448
Unevaluable investigation	103.50	21.73	18	22345	15	34934553
Death	99.64	21.73	509	21854	397540	34537028
Acute kidney injury	83.14	21.73	46	22317	304942	34629626
Hypercalcaemia	82.87	21.73	73	22290	15395	34919173
Hungry bone syndrome	80.73	21.73	17	22346	68	34934500
Toxicity to various agents	79.17	21.73	16	22347	200346	34734222
Blood phosphorus increased	77.76	21.73	53	22310	7668	34926900
Malaise	75.91	21.73	276	22087	185549	34749019
Abdominal pain upper	74.15	21.73	150	22213	71340	34863228
Neutropenia	67.42	21.73	10	22353	156768	34777800
Peritonitis bacterial	66.47	21.73	44	22319	6066	34928502
Pyrexia	64.48	21.73	71	22292	332942	34601626
Parathyroid hyperplasia	63.34	21.73	11	22352	9	34934559
Parathyroid disorder	59.16	21.73	12	22351	38	34934530
Surgery	56.96	21.73	57	22306	14100	34920468
Gastrointestinal disorder	54.17	21.73	86	22277	33862	34900706
Decreased appetite	52.45	21.73	228	22135	166164	34768404
Nephrogenic systemic fibrosis	51.38	21.73	32	22331	3973	34930595
Gastrostomy	50.71	21.73	19	22344	759	34933809
Parathyroid tumour malignant	50.02	21.73	9	22354	11	34934557
Condition aggravated	49.43	21.73	31	22332	192165	34742403
Gastrointestinal tube insertion	48.62	21.73	21	22342	1218	34933350
Drug interaction	48.44	21.73	44	22319	225902	34708666
Mastication disorder	47.14	21.73	21	22342	1312	34933256
Adjusted calcium decreased	46.37	21.73	8	22355	6	34934562
Unevaluable event	45.84	21.73	78	22285	32512	34902056
Dialysis	44.86	21.73	45	22318	11163	34923405
Blood phosphorus abnormal	42.49	21.73	11	22352	123	34934445
Treatment noncompliance	41.84	21.73	69	22294	28031	34906537
Fatigue	41.46	21.73	112	22251	370541	34564027
Disease progression	39.88	21.73	10	22353	108067	34826501
Leg amputation	39.86	21.73	22	22341	2182	34932386
Hyperparathyroidism	39.22	21.73	18	22345	1206	34933362
Gastric disorder	37.52	21.73	43	22320	12398	34922170
Platelet count decreased	37.22	21.73	15	22348	119702	34814866
Product use in unapproved indication	36.07	21.73	15	22348	117484	34817084
Overdose	34.43	21.73	8	22355	91051	34843517
Alanine aminotransferase increased	32.82	21.73	6	22357	80809	34853759
Brown tumour	31.78	21.73	5	22358	0	34934568
Dyspnoea	31.68	21.73	129	22234	376653	34557915
Drug effective for unapproved indication	31.40	21.73	20	22343	2582	34931986
White blood cell count decreased	31.26	21.73	11	22352	95434	34839134
Confusional state	30.94	21.73	28	22335	144132	34790436
Shunt stenosis	29.85	21.73	13	22350	769	34933799
Hyponatraemia	29.83	21.73	8	22355	82683	34851885
Peritonitis	29.67	21.73	44	22319	16321	34918247
Skin induration	29.66	21.73	18	22345	2133	34932435
High turnover osteopathy	29.43	21.73	5	22358	3	34934565
Haemoglobin increased	28.75	21.73	21	22342	3388	34931180
Shunt occlusion	28.52	21.73	13	22350	857	34933711
Neuropathy peripheral	28.31	21.73	9	22354	83254	34851314
Appetite disorder	27.37	21.73	18	22345	2453	34932115
Thrombocytopenia	26.27	21.73	37	22326	156210	34778358
Hyperphosphataemia	25.90	21.73	22	22341	4415	34930153
Thyroid operation	25.67	21.73	5	22358	12	34934556
Anaemia	25.65	21.73	71	22292	233264	34701304
Wrong technique in product usage process	25.53	21.73	65	22298	35921	34898647
Nephrocalcinosis	25.48	21.73	11	22352	637	34933931
Product use issue	25.02	21.73	5	22358	63211	34871357
Weight decreased	24.74	21.73	47	22316	176254	34758314
Vestibular neuronitis	24.54	21.73	8	22355	210	34934358
Hyperparathyroidism secondary	23.91	21.73	14	22349	1554	34933014
Rhabdomyolysis	23.83	21.73	7	22356	68156	34866412
Calcinosis	23.65	21.73	11	22352	760	34933808
Aspartate aminotransferase increased	23.63	21.73	7	22356	67776	34866792
Parathyroid gland enlargement	22.81	21.73	7	22356	150	34934418
Pulmonary embolism	22.32	21.73	15	22348	89731	34844837
Pancytopenia	22.23	21.73	17	22346	95140	34839428

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Laboratory test abnormal	9734.53	16.78	2293	33407	25755	79682933
Hospitalisation	5877.21	16.78	2016	33684	92220	79616468
Product dose omission issue	3036.05	16.78	1681	34019	245856	79462832
Blood parathyroid hormone increased	1060.23	16.78	257	35443	3188	79705500
Blood parathyroid hormone abnormal	761.85	16.78	134	35566	241	79708447
Arteriovenous fistula site complication	730.40	16.78	151	35549	838	79707850
Adverse drug reaction	483.32	16.78	325	35375	66067	79642621
Nausea	475.87	16.78	1203	34497	955993	78752695
Vomiting	376.65	16.78	881	34819	664947	79043741
Decreased appetite	349.00	16.78	581	35119	341837	79366851
Calciphylaxis	347.16	16.78	109	35591	3661	79705027
Living in residential institution	346.13	16.78	77	35623	633	79708055
Hypocalcaemia	331.48	16.78	231	35469	49693	79658995
Death	328.02	16.78	757	34943	565757	79142931
Rehabilitation therapy	294.55	16.78	82	35618	1795	79706893
Blood calcium increased	268.28	16.78	118	35582	10282	79698406
Parathyroid tumour benign	266.81	16.78	64	35636	755	79707933
Abdominal discomfort	233.33	16.78	409	35291	250318	79458370
Unevaluable investigation	231.42	16.78	39	35661	46	79708642
Malaise	207.20	16.78	582	35118	489287	79219401
Blood calcium abnormal	205.73	16.78	58	35642	1331	79707357
Hungry bone syndrome	203.40	16.78	40	35660	164	79708524
Renal transplant	186.94	16.78	62	35638	2485	79706203
Muscle spasms	168.85	16.78	290	35410	174440	79534248
Intentional product misuse	160.04	16.78	205	35495	94960	79613728
Blood calcium decreased	158.74	16.78	124	35576	31695	79676993
Peritonitis bacterial	158.55	16.78	80	35620	9487	79699201
Hypercalcaemia	154.36	16.78	132	35568	38298	79670390
Abdominal pain upper	143.21	16.78	312	35388	223507	79485181
Parathyroidectomy	141.68	16.78	30	35670	190	79708498
Blood parathyroid hormone decreased	140.04	16.78	76	35624	10460	79698228
Nephrogenic systemic fibrosis	133.80	16.78	62	35638	6098	79702590
Unevaluable event	130.38	16.78	142	35558	55443	79653245
Blood phosphorus increased	124.78	16.78	70	35630	10277	79698411
Parathyroid tumour malignant	113.31	16.78	20	35680	37	79708651
Hyperparathyroidism	107.83	16.78	44	35656	3180	79705508
Brown tumour	99.47	16.78	18	35682	41	79708647
Surgery	97.23	16.78	95	35605	32671	79676017
Dialysis	92.18	16.78	72	35628	18390	79690298
Adjusted calcium decreased	91.24	16.78	21	35679	204	79708484
Toxicity to various agents	86.97	16.78	40	35660	421500	79287188
Pyrexia	85.72	16.78	107	35593	678602	79030086
Skin induration	84.36	16.78	41	35659	4484	79704204
Transplant	83.93	16.78	27	35673	981	79707707
Febrile neutropenia	83.40	16.78	5	35695	230994	79477694
Parathyroid disorder	78.95	16.78	22	35678	483	79708205
Gastrointestinal tube insertion	78.53	16.78	29	35671	1601	79707087
Rheumatoid arthritis	76.84	16.78	4	35696	208466	79500222
Hypophagia	76.63	16.78	98	35602	45269	79663419
Shunt occlusion	73.35	16.78	27	35673	1477	79707211
Neutropenia	71.72	16.78	20	35680	287690	79420998
Condition aggravated	70.84	16.78	72	35628	501052	79207636
Arthralgia	70.22	16.78	92	35608	571711	79136977
Gastric disorder	69.84	16.78	85	35615	37348	79671340
Gastrostomy	67.87	16.78	24	35676	1169	79707519
Hypervolaemia	65.56	16.78	88	35612	42602	79666086
Arteriovenous fistula occlusion	63.76	16.78	19	35681	533	79708155
Joint swelling	63.31	16.78	25	35675	288621	79420067
Hyperphosphataemia	63.24	16.78	38	35662	6338	79702350
Hepatic enzyme increased	62.86	16.78	5	35695	182605	79526083
Fatigue	62.47	16.78	211	35489	929516	78779172
Blood phosphorus abnormal	60.89	16.78	16	35684	279	79708409
Shunt stenosis	60.64	16.78	23	35677	1368	79707320
Peritonitis	59.49	16.78	68	35632	27968	79680720
Skin hypertrophy	58.49	16.78	33	35667	4895	79703793
Parathyroid hyperplasia	58.37	16.78	14	35686	165	79708523
Drug interaction	58.25	16.78	60	35640	415123	79293565
Sinusitis	58.14	16.78	9	35691	195492	79513196
Contraindicated product administered	58.12	16.78	3	35697	157535	79551153
Skin tightness	57.61	16.78	34	35666	5488	79703200
Leg amputation	55.94	16.78	29	35671	3637	79705051
Product use issue	55.32	16.78	13	35687	209809	79498879
Diarrhoea	53.89	16.78	616	35084	879873	78828815
End stage renal disease	53.22	16.78	44	35656	12176	79696512
Peritoneal dialysis complication	52.08	16.78	24	35676	2330	79706358
High turnover osteopathy	50.65	16.78	10	35690	42	79708646
Arteriovenous fistula thrombosis	50.45	16.78	16	35684	555	79708133
Malignant neoplasm progression	48.90	16.78	3	35697	135987	79572701
Skin fibrosis	48.25	16.78	20	35680	1504	79707184
Pelvic deformity	45.64	16.78	10	35690	76	79708612
Product use in unapproved indication	43.97	16.78	29	35671	250330	79458358
Parathyroid gland enlargement	43.60	16.78	11	35689	162	79708526
White blood cell count decreased	43.47	16.78	15	35685	188273	79520415
Alanine aminotransferase increased	42.99	16.78	10	35690	162560	79546128
Arthropathy	42.85	16.78	13	35687	177098	79531590
Appetite disorder	42.62	16.78	32	35668	7707	79700981
Blue toe syndrome	41.83	16.78	14	35686	577	79708111
Acute kidney injury	41.16	16.78	109	35591	519295	79189393
Stomatitis	40.90	16.78	8	35692	146749	79561939
Injection site pain	40.90	16.78	5	35695	129833	79578855
Cardiac operation	39.95	16.78	26	35674	4986	79703702
Platelet count decreased	39.27	16.78	19	35681	194645	79514043
Arteriovenous fistula site infection	38.18	16.78	10	35690	172	79708516
Parathyroid haemorrhage	37.84	16.78	6	35694	3	79708685
Therapeutic procedure	37.12	16.78	14	35686	820	79707868
Intentional product use issue	37.09	16.78	11	35689	152101	79556587
Weight increased	36.74	16.78	42	35658	277344	79431344
Angina pectoris	36.33	16.78	75	35625	51657	79657031
Therapeutic product effect decreased	36.22	16.78	14	35686	163849	79544839
Arteriovenous fistula site haemorrhage	35.71	16.78	11	35689	346	79708342
Nephrocalcinosis	35.39	16.78	16	35684	1486	79707202
Wrong technique in product usage process	35.25	16.78	92	35608	73783	79634905
Treatment noncompliance	33.49	16.78	73	35627	52195	79656493
Joint contracture	32.96	16.78	18	35682	2506	79706182
Pericarditis	32.86	16.78	4	35696	104232	79604456
Treatment failure	32.37	16.78	18	35682	170468	79538220
Lower respiratory tract infection	32.14	16.78	9	35691	129211	79579477
Hyperparathyroidism secondary	32.08	16.78	18	35682	2642	79706046
Shunt infection	32.07	16.78	9	35691	203	79708485
Neuropathy peripheral	31.35	16.78	12	35688	141293	79567395
Chronic kidney disease-mineral and bone disorder	31.22	16.78	11	35689	530	79708158
Rash	30.62	16.78	144	35556	578214	79130474
Aspartate aminotransferase increased	30.38	16.78	12	35688	138629	79570059
Glossodynia	30.16	16.78	5	35695	103332	79605356
Fistula repair	30.05	16.78	7	35693	72	79708616
Arrhythmia	29.94	16.78	77	35623	61195	79647493
Cerebrovascular accident	29.73	16.78	143	35557	155149	79553539
Wheezing	29.25	16.78	8	35692	116656	79592032
Systemic lupus erythematosus	29.10	16.78	9	35691	121140	79587548
Hypotension	29.04	16.78	313	35387	440004	79268684
Thyroid operation	28.78	16.78	8	35692	174	79708514
Constipation	28.76	16.78	221	35479	282829	79425859
Haemoglobin increased	28.64	16.78	23	35677	6109	79702579
Calcinosis	28.51	16.78	16	35684	2349	79706339
Toe amputation	28.06	16.78	19	35681	3892	79704796
Blood pressure increased	27.98	16.78	32	35668	211328	79497360
Confusional state	27.28	16.78	64	35636	317933	79390755
Blood cholesterol increased	26.92	16.78	3	35697	83717	79624971
Psoriasis	26.90	16.78	4	35696	89583	79619105
Phosphaturic mesenchymal tumour	26.85	16.78	4	35696	0	79708688
Thrombosis in device	26.68	16.78	21	35679	5421	79703267
COVID-19	25.40	16.78	20	35680	157654	79551034
Parathyroid gland operation	25.33	16.78	5	35695	21	79708667
Hyperparathyroidism tertiary	25.33	16.78	5	35695	21	79708667
Hyperparathyroidism primary	25.15	16.78	9	35691	454	79708234
Fibrosis	24.98	16.78	20	35680	5289	79703399
Drug effective for unapproved indication	24.87	16.78	21	35679	5980	79702708
Alopecia	24.63	16.78	41	35659	231314	79477374
Hepatic cyst infection	24.49	16.78	7	35693	169	79708519
Swelling	24.40	16.78	37	35663	216674	79492014
Dyspnoea	24.32	16.78	256	35444	856769	78851919
Medical procedure	24.01	16.78	8	35692	325	79708363
Parathyroid tumour	24.00	16.78	6	35694	85	79708603
Pain	23.91	16.78	201	35499	703601	79005087
Hypercalciuria	23.80	16.78	9	35691	531	79708157
Mucosal inflammation	23.58	16.78	3	35697	75577	79633111
Hospice care	23.54	16.78	26	35674	10298	79698390
Drug ineffective	23.49	16.78	342	35358	1080571	78628117
Paraesthesia	23.41	16.78	147	35553	176176	79532512
Skin hyperpigmentation	23.22	16.78	22	35678	7281	79701407
Gastrointestinal disorder	23	16.78	112	35588	122093	79586595
Overdose	22.17	16.78	30	35670	184176	79524512
Blood pressure abnormal	21.34	16.78	32	35668	17137	79691551
Neoplasm malignant	21.03	16.78	45	35655	31765	79676923
Loss of personal independence in daily activities	20.70	16.78	10	35690	102570	79606118
Asthma	20.69	16.78	18	35682	135077	79573611
Intermittent claudication	20.57	16.78	15	35685	3456	79705232
Aplasia pure red cell	20.15	16.78	21	35679	7789	79700899
Parathyroid cyst	20.14	16.78	3	35697	0	79708688
Cardiac disorder	20.10	16.78	70	35630	65687	79643001
Blood bilirubin increased	19.79	16.78	3	35697	66229	79642459
Wound	19.66	16.78	14	35686	116165	79592523
Rhabdomyolysis	19.41	16.78	11	35689	103120	79605568
Blood phosphorus decreased	19.15	16.78	19	35681	6649	79702039
Extremity contracture	18.95	16.78	11	35689	1721	79706967
Renal cyst infection	18.95	16.78	6	35694	207	79708481
Oxygen saturation decreased	18.80	16.78	18	35682	129029	79579659
Foot amputation	18.74	16.78	9	35691	959	79707729
Migraine	18.48	16.78	8	35692	87485	79621203
Intracardiac mass	18.47	16.78	6	35694	225	79708463
Blood glucose decreased	18.37	16.78	38	35662	26196	79682492
Oncocytoma	18.30	16.78	4	35696	30	79708658
Pancytopenia	17.99	16.78	29	35671	165716	79542972
Nasal congestion	17.83	16.78	6	35694	76546	79632142
Vestibular neuronitis	17.78	16.78	8	35692	735	79707953
Gangrene	17.77	16.78	21	35679	8943	79699745
Poor peripheral circulation	17.60	16.78	14	35686	3669	79705019
Drug hypersensitivity	17.25	16.78	72	35628	298844	79409844
Anaphylactic reaction	17.15	16.78	8	35692	83735	79624953
Blister	17.02	16.78	17	35683	119459	79589229
Liver function test abnormal	16.97	16.78	4	35696	64471	79644217
Urticaria	16.91	16.78	36	35664	185165	79523523
Osteoarthritis	16.88	16.78	9	35691	87300	79621388

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	H05BX01	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS CALCIUM HOMEOSTASIS ANTI-PARATHYROID AGENTS Other anti-parathyroid agents
FDA MoA	N0000020081	Increased Calcium-sensing Receptor Sensitivity
MeSH PA	D057966	Calcimimetic Agents
MeSH PA	D000077264	Calcium-Regulating Hormones and Agents
MeSH PA	D006727	Hormone Antagonists
FDA EPC	N0000175902	Calcium-sensing Receptor Agonist
CHEBI has role	CHEBI:48525	calcimimetics
CHEBI has role	CHEBI:50183	P450 inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Hypercalcemia due to Primary Hyperparathyroidism	indication
Hyperparathyroidism Secondary to Chronic Renal Failure with Dialysis	indication
Parathyroid Carcinoma with Hypercalcemia	indication
Hypophosphatemia	contraindication	4996001
Hypocalcemia	contraindication	5291005
Low blood pressure	contraindication	45007003
Chronic heart failure	contraindication	48447003
Seizure disorder	contraindication	128613002
Disease of liver	contraindication	235856003	DOID:409
Adynamic bone disease	contraindication	236552002

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	8.69	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
EQ 30MG BASE	SENSIPAR	AMGEN	N021688	March 8, 2004	RX	TABLET	ORAL	7829595	Sept. 22, 2026	METHOD OF TREATING HYPERPARATHYROIDISM; METHOD OF TREATING HYPERCALCEMIA
EQ 60MG BASE	SENSIPAR	AMGEN	N021688	March 8, 2004	RX	TABLET	ORAL	7829595	Sept. 22, 2026	METHOD OF TREATING HYPERPARATHYROIDISM; METHOD OF TREATING HYPERCALCEMIA
EQ 90MG BASE	SENSIPAR	AMGEN	N021688	March 8, 2004	RX	TABLET	ORAL	7829595	Sept. 22, 2026	METHOD OF TREATING HYPERPARATHYROIDISM; METHOD OF TREATING HYPERCALCEMIA

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Extracellular calcium-sensing receptor	GPCR	P41180	CASR_HUMAN	POSITIVE ALLOSTERIC MODULATOR	EC50	7.70	CHEMBL	CHEMBL
Cytochrome P450 2D6	Enzyme	P10635	CP2D6_HUMAN		IC50	7.30	CHEMBL
Glycine receptor subunit alpha-1	Ion channel	P23415	GLRA1_HUMAN		EC50	6.49	CHEMBL
Metabotropic glutamate receptor 5	GPCR		GRM5_RAT	ALLOSTERIC MODULATOR	Ki	4.35	IUPHAR

External reference:

ID	Source
4021430	VUID
N0000148841	NUI
D03504	KEGG_DRUG
364782-34-3	SECONDARY_CAS_RN
384379	RXNORM
4021430	VANDF
C1337242	UMLSCUI
CHEBI:48390	CHEBI
CHEMBL1201284	ChEMBL_ID
CHEMBL1200776	ChEMBL_ID
DB01012	DRUGBANK_ID
D000069449	MESH_DESCRIPTOR_UI
156419	PUBCHEM_CID
3308	IUPHAR_LIGAND_ID
8287	INN_ID
UAZ6V7728S	UNII
18133	MMSL
303128	MMSL
49840	MMSL
d05218	MMSL
008595	NDDF
008596	NDDF
409391006	SNOMEDCT_US
409392004	SNOMEDCT_US
426512007	SNOMEDCT_US
YP4	PDB_CHEM_ID

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Cinacalcet	HUMAN PRESCRIPTION DRUG LABEL	1	0904-7067	TABLET, FILM COATED	30 mg	ORAL	ANDA	25 sections
Cinacalcet	Human Prescription Drug Label	1	16714-078	TABLET, FILM COATED	30 mg	ORAL	ANDA	27 sections
Cinacalcet	Human Prescription Drug Label	1	16714-078	TABLET, FILM COATED	30 mg	ORAL	ANDA	27 sections
Cinacalcet	Human Prescription Drug Label	1	16714-079	TABLET, FILM COATED	60 mg	ORAL	ANDA	27 sections
Cinacalcet	Human Prescription Drug Label	1	16714-079	TABLET, FILM COATED	60 mg	ORAL	ANDA	27 sections
Cinacalcet	Human Prescription Drug Label	1	16714-080	TABLET, FILM COATED	90 mg	ORAL	ANDA	27 sections
Cinacalcet	Human Prescription Drug Label	1	16714-080	TABLET, FILM COATED	90 mg	ORAL	ANDA	27 sections
CINACALCET	HUMAN PRESCRIPTION DRUG LABEL	1	16729-440	TABLET, FILM COATED	30 mg	ORAL	ANDA	25 sections
CINACALCET	HUMAN PRESCRIPTION DRUG LABEL	1	16729-441	TABLET, FILM COATED	60 mg	ORAL	ANDA	25 sections
CINACALCET	HUMAN PRESCRIPTION DRUG LABEL	1	16729-442	TABLET, FILM COATED	90 mg	ORAL	ANDA	25 sections
Cinacalcet	Human Prescription Drug Label	1	31722-103	TABLET, FILM COATED	30 mg	ORAL	ANDA	29 sections
Cinacalcet	Human Prescription Drug Label	1	31722-104	TABLET, FILM COATED	60 mg	ORAL	ANDA	29 sections
Cinacalcet	Human Prescription Drug Label	1	31722-105	TABLET, FILM COATED	90 mg	ORAL	ANDA	29 sections
Cinacalcet	HUMAN PRESCRIPTION DRUG LABEL	1	42291-459	TABLET, FILM COATED	30 mg	ORAL	ANDA	25 sections
Cinacalcet	HUMAN PRESCRIPTION DRUG LABEL	1	42291-459	TABLET, FILM COATED	30 mg	ORAL	ANDA	25 sections
Cinacalcet	HUMAN PRESCRIPTION DRUG LABEL	1	42291-460	TABLET, FILM COATED	60 mg	ORAL	ANDA	25 sections
Cinacalcet	HUMAN PRESCRIPTION DRUG LABEL	1	42291-460	TABLET, FILM COATED	60 mg	ORAL	ANDA	25 sections
Cinacalcet	HUMAN PRESCRIPTION DRUG LABEL	1	42291-461	TABLET, FILM COATED	90 mg	ORAL	ANDA	25 sections
Cinacalcet	HUMAN PRESCRIPTION DRUG LABEL	1	42291-461	TABLET, FILM COATED	90 mg	ORAL	ANDA	25 sections
Cinacalcet	HUMAN PRESCRIPTION DRUG LABEL	1	42543-961	TABLET, FILM COATED	30 mg	ORAL	ANDA	23 sections
Cinacalcet	HUMAN PRESCRIPTION DRUG LABEL	1	42543-961	TABLET, FILM COATED	30 mg	ORAL	ANDA	23 sections
Cinacalcet	HUMAN PRESCRIPTION DRUG LABEL	1	42543-962	TABLET, FILM COATED	60 mg	ORAL	ANDA	23 sections
Cinacalcet	HUMAN PRESCRIPTION DRUG LABEL	1	42543-962	TABLET, FILM COATED	60 mg	ORAL	ANDA	23 sections
Cinacalcet	HUMAN PRESCRIPTION DRUG LABEL	1	42543-963	TABLET, FILM COATED	90 mg	ORAL	ANDA	23 sections
Cinacalcet	HUMAN PRESCRIPTION DRUG LABEL	1	42543-963	TABLET, FILM COATED	90 mg	ORAL	ANDA	23 sections
Cinacalcet	HUMAN PRESCRIPTION DRUG LABEL	1	43598-367	TABLET	30 mg	ORAL	ANDA	24 sections
Cinacalcet	HUMAN PRESCRIPTION DRUG LABEL	1	43598-368	TABLET	60 mg	ORAL	ANDA	24 sections
Cinacalcet	HUMAN PRESCRIPTION DRUG LABEL	1	43598-369	TABLET	90 mg	ORAL	ANDA	24 sections
Cinacalcet	Human Prescription Drug Label	1	47335-379	TABLET, FILM COATED	30 mg	ORAL	ANDA	27 sections
Cinacalcet	Human Prescription Drug Label	1	47335-380	TABLET, FILM COATED	60 mg	ORAL	ANDA	27 sections